Based on immuno-reactive score (IRS) analysis, we noted that NRF2 was localized predominantly in cell nuclei, and both nuclear and cytosolic NRF2 levels increased significantly with malignant progression, i.e., progression from tumor-adjacent normal epithelia to epithelial dysplasia to squamous cell carcinoma (Figure 1B). The gene discussed is NFE2L2; the disease is squamous cell carcinoma.